Kinex Pharmaceuticals, LLC announced today that The Oishei Foundation has made an investment in the current Series A1 round of Financing.

The John R. Oishei Foundation is the area’s largest private foundation with assets in excess of $260 million. The Foundation is committed to devoting their time, people and networks to convening stakeholders around issues; initiating support and collaboration; sharing knowledge; building nonprofits’ organizational capacity; and supporting the development of promising leaders in all communities and sectors. The investment in Kinex Pharmaceuticals was reviewed by the Foundation’s investment committee with assistance from an outside consultant to ensure that the investment maximizes opportunity for the foundation while minimizing risk and enhancing community health and medical research, to meet its mission. Read more>

Kinex Pharmaceuticals, LLC announced today that Dr. David Hangauer, who served as the Founding Senior Vice President of Research, will be appointed as Chief Scientific Officer of the Company. Read more>

Kinex Pharmaceuticals, LLC announced today that Dr. Allen Barnett, who served as the Founding Chief Executive Officer, has decided to step aside as CEO. Read more>

Kinex Pharmaceuticals, LLC announced today that Mr. Chuck Lannon, who serves as Vice-Chairman of the Board, has been elected to the Board of Directors of The Hauptman-Woodward Medical Research Institute. Read more>

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.
Read more>